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Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, highly aggressive hematopoietic malignancy that is characterized by cutaneous and bone marrow involvement and leukemic spread, representing 0.7% of primary cutaneous lymphomas 1 . Formerly known as CD4＋/CD56＋ hematodermic neoplasm or blastic NK-cell lymphoma 2 , BPDCN is derived from precursors of plasmacytoid dendritic cells and was only recently established as a distinct entity 3 .
A 74-year-old man presented with a 4-month history of asymptomatic cutaneous lesions that initially appeared on his face but progressively spread to his thorax and arms. He had no systemic symptoms. His medical history included peripheral arterial disease and dyslipidemia, for which he was on acenocumarol and rosuvastatin. Physical examination revealed infiltrated violaceous plaques and nodules on his face and thorax and firm subcutaneous nodules on his arms along with reticulated purpuric macules (Fig. 1 4, 5 . Bone marrow is involved in most cases, and practically any organ can be affected. The disease follows a short course and fulminant leukemia is the common terminal stage [4] [5] [6] . The diagnosis relies on the immunophenotypic features of the malignant cells. FCM is preferred over immunohistochemical analysis since it allows for the examination of more markers and their intensity determination 7, 8 . The expression of CD4, CD56, and CD123 in the absence of T-cell, B-cell, or myeloid markers defines BPDCN [4] [5] [6] [7] [8] . The correct diagnosis implies an appropriate panel of antibodies; in contrast, insufficient knowledge on this entity and inadequate immunophenotypic investigation can lead to the misdiagnosis of a different leukemia 8 .
Cytogenetic analysis is not helpful since no recurrent specific chromosomal aberrations were recognized 7, 8 . The prognosis of patients with BPDCN is poor, with a median survival of 12∼14 months regardless of treatment type 9 .
Acute lymphoblastic leukemia-type treatment regimens are advised and a promising initial response may occur, but is followed by quick relapse 6, 9, 10 . Long-term remissions have been rarely reported in younger patients who received acute leukemia-type induction therapy and allogeneic stem cell transplantation [9] [10] [11] .
Although clarification of the immunophenotypic features of BPDCN has improved its recognition, this entity remains a diagnostic challenge. Cutaneous lesions are usually the only sign of the disease, so dermatologists should be knowledgeable about it and play a crucial role in uncovering this malignancy and avoiding diagnostic delays. 
